{
  "ticker": "JNJ",
  "date": "2022-02-07",
  "lookback_days": 14,
  "fetched_at": "2026-02-13T11:43:11.226589",
  "source": "alpha_vantage",
  "article_count": 4,
  "articles": [
    {
      "title": "Johnson & Johnson Reports Q4 and Full-Year 2021 Results",
      "summary": "Johnson & Johnson announced strong financial results for the fourth quarter and full-year 2021, showing growth across all business segments. The company reported full-year sales of $93.8 billion, a 13.6% increase, and provided 2022 guidance for adjusted operational sales growth of 7.7% and adjusted operational EPS growth of 9.2%. CEO Joaquin Duato highlighted the company's strong results, financial profile, and innovative pipeline positioning it for future success.",
      "url": "https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2021-results",
      "source": "Johnson & Johnson",
      "published": "20220125T171642",
      "overall_sentiment_score": 0.404804,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment_score": 0.403514,
      "ticker_sentiment_label": "Bullish",
      "relevance_score": 1.0
    },
    {
      "title": "Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy",
      "summary": "Capricor Therapeutics has secured a new U.S. commercialization and distribution deal with Nippon Shinyaku for its lead Duchenne muscular dystrophy (DMD) candidate, CAP-1002, worth up to $735 million. This partnership comes five years after Johnson & Johnson's Janssen subsidiary ended a previous collaboration for the cell therapy. Capricor plans to use this deal to support its pivotal Phase III HOPE-3 trial for CAP-1002 in DMD, aiming to differentiate its immune-modulating approach from other gene therapies.",
      "url": "https://www.genengnews.com/gen-edge/same-drug-new-partner-capricor-in-up-to-735m-deal-for-dmd-cell-therapy/",
      "source": "Genetic Engineering and Biotechnology News",
      "published": "20220201T162146",
      "overall_sentiment_score": 0.239232,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.110043,
      "ticker_sentiment_label": "Neutral",
      "relevance_score": 0.769498
    },
    {
      "title": "Native American tribes reach $590 million opioid settlement with J&J, drug distributors",
      "summary": "Native American tribes have reached a $590 million opioid settlement with Johnson & Johnson and the three largest U.S. drug distributors (McKesson Corp., AmerisourceBergen Corp., and Cardinal Health Inc.). This deal aims to resolve claims that the companies fueled an opioid crisis in their communities, with the funds earmarked for addiction treatment and services. This settlement is separate from a larger $26 billion deal but allows J&J to deduct its contribution from its share of that broader agreement.",
      "url": "https://www.cbc.ca/news/health/native-american-tribes-opioid-crisis-settlement-johnson-1.6335438",
      "source": "CBC",
      "published": "20220201T152500",
      "overall_sentiment_score": -0.249096,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment_score": -0.239336,
      "ticker_sentiment_label": "Somewhat-Bearish",
      "relevance_score": 0.939576
    },
    {
      "title": "Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO",
      "summary": "Belgian drugmaker Galapagos NV has appointed Paul Stoffels, former chief scientific officer of Johnson & Johnson, as its new CEO, effective April 1. Stoffels previously spearheaded the development of J&J's single-shot COVID-19 vaccine and has a long history with Galapagos, having served on its board from 1999 to 2002. He will succeed co-founder Onno van de Stolpe, who is retiring.",
      "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-galapagos-names-former-jj-exec-paul-stoffels-ceo-2022-01-26/",
      "source": "Reuters",
      "published": "20220126T230100",
      "overall_sentiment_score": 0.247171,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment_score": 0.21089,
      "ticker_sentiment_label": "Somewhat-Bullish",
      "relevance_score": 0.89059
    }
  ]
}